Studies have found that the risk of MIS-C after COVID-19 vaccination is reduced by a factor of one million.

February 23, 2022 Read for 2 minutes Source / Disclosure Disclosure: Son and Yousaf have not reported disclosure of relevant financial information. Chang reports that it is funded by GlaxoSmithKline for researcher-led research that has nothing to do with comments. See Surveys for disclosure of relevant financial information for all other authors. Add topics to email alerts Receive an email when a new article is posted Please enter your email address to receive emails when new articles are posted .. "data-action " subscribe "> Subscribe The request could not be processed. Please try again later.If you continue to have this issue, please contact us customerservice@slackinc.com.. Return to Healio Risk Pediatric multisystem inflammatory syndromeOr MIS-C, researchers report that a person's at least one dose of the COVID-19 vaccine reduces it by a factor of one million. Lancet Child & Adolcent Health. This is "substantially lower" than previous estimates of MIS-C (about 200 cases per million) in unvaccinated US adolescents with confirmed SARS-CoV-2 infection, according to the CDC study. Said. Anna R. Youssaf, MDAnd a colleague reported. "As part of a comprehensive effort to monitor the safety of the COVID-19 vaccine in the United States, the CDC has closely monitored MIS-C cases in vaccinated children," Yousaf press. Described in the release. "Our results suggest that MIS-C cases after COVID-19 vaccination are rare and that unvaccinated children infected with COVID-19 are much more likely to develop MIS-C. doing." The CDC presents cases of MIS-C with evidence of fever, inflammation, and clinically serious illness requiring hospitalization, involving more than one organ, and a plausible alternative diagnosis. Not reported to be positive for current or recent SARS-CoV-2 infection, or exposed to suspected or confirmed cases of COVID-19. Yousaf et al. Have data that reflect the first months of the COVID-19 vaccine deployment in the United States from December 14, 2020 to August 31, 2021, and potential for 12-year-olds. We investigated 47 reports of MIS-C disease. Up to 20 years after administration of COVID-19 vaccine. Of more than 21 million children and adolescents in this age group who received at least one COVID-19 vaccine during the study, researchers identified only 21 MIS-C cases, "post-vaccinated MIS. -The overall reporting rate for C is now one. Cases per million people who received one or more vaccinations in this age group. " They divided cases with and without evidence of past or recent SARS-CoV-2 infection. Of the 21 confirmed cases, 15 (71%) had evidence of past or recent SARS-CoV-2 infection. The remaining 6 (29%) were not, at a rate of 0.3 per million vaccinated individuals. "As with the individuals in our study who had evidence of previous infection outside the normal period of onset of MIS-C, the contribution of vaccination to the disease of individuals without evidence of infection is unknown and I Our surveillance data, "they wrote. "Some of these six may have had other unrecognized inflammatory conditions." In the comments accompanying the research, Joyce C. Chang MD, MSCE, The doctor in charge of rheumatology at Boston Children's Hospital, and Mary Bethson, MDThe findings are "very encouraging overall," said the director of rheumatology at Boston Children. "This timely report is of particular interest to healthcare providers, scientists and policy makers, given the ongoing widespread infection of Omicron variants," they write. However, there are still unanswered questions. "It is unclear whether currently available vaccines provide similar protection against MIS-C due to the different variants of SARS-CoV-2," they write. "In addition, as the usefulness of serological tests diminishes in the rise of seroprevalence, better diagnostic tools for MIS-C are needed. The data presented by Yousaf and colleagues are: It indicates that alternative diagnoses need to be carefully considered among vaccinated children with clinical syndromes that mimic MIS-C. reference: Chang JC, Son MBF Lancet.. 2022; doi: 10.1016 / S2352-4642 (22) 00061-X.. Yousaf A, et al. Lancet.. 2022; doi: 10.1016 / S2352-4642 (22) 00028-1.. Add topics to email alerts Receive an email when a new article is posted Please enter your email address to receive emails when new articles are posted .. "data-action " subscribe "> Subscribe The request could not be processed. Please try again later.If you continue to have this issue, please contact us customerservice@slackinc.com.. Return to Healio COVID-19 Resource Center Sources 1/ https://Google.com/ 2/ https://www.healio.com/news/primary-care/20220223/misc-risk-after-covid19-vaccination-falls-to-one-in-a-million-study-finds The mention sources can contact us to remove/changing this article

ExBulletin

Studies have found that the risk of MIS-C after COVID-19 vaccination is reduced by a factor of one million.

Health

Studies have found that the risk of MIS-C after COVID-19 vaccination is reduced by a factor of one million.

reference:

COVID-19 Resource Center

Related

Recent Posts

Add ExBulletin to your Home screen!